Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses

v3.19.3
Accrued Expenses
 9 Months Ended
Sep. 30, 2019
Payables and Accruals [Abstract]  
Accrued Expenses

7. ACCRUED EXPENSES

 

Accrued expenses consisted of the following:

 

    September 30, 2019     December 31, 2018  
             
Accrued clinical operations and trials costs   $ 11,810,266     $ 4,914,881  
Accrued product development costs     6,740,406       2,222,093  
Accrued compensation     3,891,456       2,253,621  
Accrued other     1,527,175       460,596  
Total   $ 23,969,303     $ 9,851,191